WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

3  China Stock Picks https://www.morningstar.co.uk/uk/news/208822/3-china-stock-picks.aspx VIDEO: JPMorgan China Growth & Income Trust manager Rebecca Jiang looks at opportunities in Chinese e-commerce, biotech and software stocks ...

HSBC Round License" WuXi's share price is like a broken bamboo, if you want to chase long positions, you can pay attention to the bull 55020 http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1071487/2 WuXi (02269) surged 18% last week, making it the second best performing stock in the HSI. Beishui took the opportunity to make a net outflow of RMB 200 million. A major bank pointed out that WuXi is pushing more customers to adopt its platform during the pandemic situation. According to Bloomberg, the target price of major banks in January is between 120-153.10 yuan, all of which are buy/run. Win the market rating. WuXi PharmaTech (2359) announced that its annual net profit will increase by up to 60% year-on-year. Investors want to believe that WuXi’s stock price will take another step. If you have a long position, you can pay attention to WuXi Bull Stock 55020, with a call price of 104.88 yuan, which will expire in November 2021.

«THE WEEK»: WUXI BIOLOGICS MIT RIESIGEM POTENTIAL https://www.payoff.ch/news/post/the-week-wuxi-biologics-mit-riesigem-potential Als ultra-hot betrachte ich die Papiere von Wuxi Biologics (Börsensymbol: 2269 HK). Lag das Betriebsergebnis (EBIT) im Jahr 2017 bei 486 Millionen CNY, so erhöht sich dieser Wert auf 3.712 Milliarden CNY. Verrückt ist laut meinen eingesetzten Modellen die erwartete Umsatzrendite von 29.12% per 2023. Handelsempfehlung: Neu, spekulative Depotbeimischung.

https://youtu.be/Q5XIvzjGG6A

Bzgl der Baustelle in Irland: WuXi campus deemed essential construction https://www.independent.ie/regionals/argus/news/wuxi-campus-deemed-essential-construction-39979856.html

Das läuft ja super kann so weiter laufen 😉

Auch spannend was der 5y forecast sagt... https://walletinvestor.com/hkex-stock-forecast/2269-stock-prediction

Daiwa lifts Wuxi Biologics (02269) to HK$135 https://www.etnet.com.hk/www/tc/news/categorized_news_detail_eng.php?newsid=ETE310122133 ...

CCB International: Reiterate WuXi Biologics (02269) "Outperform" rating target price raised by 113% to HK$140 https://wap.eastmoney.com/a/202101211784677558.html CCB International released a research report that raised the target price of WuXi Biologics (02269) from HK$ 65.7 to HK$ 140 by 113%, and reiterated its "outperform" rating. According to the report , WuXi Biologics (02269) currently has a large backlog of new pneumonia-related orders. In the third quarter, new pneumonia-related service orders increased by US $ 170 million to US$ 700 million. , The company has orders of about 1 billion US dollars, and believes that these orders will help the company's long-term growth. The bank said that based on the current company's full use of production capacity, it is expected that the conversion rate of the above-mentioned orders will be slow, and it is also expected that the company will add 80 overall projects last year. It is believed that orders related to the new type of pneumonia have peaked, but the relevant orders have increased profit The impact of the company has not yet been reflected in the stock price. It is expected that the six projects transferred from its competitors to the company will drive its revenue in 2022. CCB International raised WuXi Biologics ' sales forecasts for this year and next year by 19% and 11%, and raised its earnings forecasts for this year and next year by 19% and 13%. It believes that the company will maintain a compound annual growth rate of at least 40% in net profit in the next three years. .

Ist auch etwas länger, deshalb bei Interesse bitte eigenständig durch den Übersetzer jagen: Citigroup first awarded WuXi Biologics (02269.HK) "Buy" target price of 130 yuan in "The Big Bank Report" http://www.aastocks.com/tc/stocks/news/aafn-con/now.1070560/latest-news

Bank of Communications International: WuXi Biologics (02269-HK) continues to expand its production capacity and the demand for later projects surges, the first to buy https://www.finet.hk/newscenter/news_content/600776c8bde0b30d4618ee82 Bank of Communications International released a report that WuXi Biologics (02269-HK) 5-10 projects will enter the commercial manufacturing stage, and related orders totaling USD 700 million to 1 billion will be completed in 2021-22; In 2021-22, it will contribute US$200-400 million in CMO revenue; 3) The number of new projects per year will be increased from 40-50 to 60-80. Production capacity continues to expand, and total CMO production capacity will increase from 54,000 liters in 2020 to 125,000/280,000 liters in 2021/23. Due to the surge in demand for later projects, the bank expects that WuXi’s new plant will have a high utilization rate, and the staff team will increase by 2,000 from the current approximately 6,600. The bank raised its 2020-22 net profit forecast by 2-5% to reflect the revenue contribution of CMOs, and based on DCF, raised its target price from HK$86.33 to HK$122.08, reiterating that WuXi is the industry’s first buy.

WuXi Biologics and Oxford BioTherapeutics join forces on second bispecific program https://www.thepharmaletter.com/article/wuxi-biologics-and-oxford-biotherapeutics-join-forces-on-second-bispecific-program

https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a210119.pdf WuXi Biologics (02269) hat aufgrund der Ausübung von Aktienoptionen insgesamt 6.146.800 Aktien ausgegeben https://m.jrj.com.cn/madapter/hk/2021/01/19223231724173.shtml WuXi Biologics (02269), gab bekannt, dass die Direktoren und Mitarbeiter des Unternehmens im Zeitraum vom 4. bis 19. Januar 2021 ihre Aktienoptionen im Rahmen des Aktienoptionsplans vor dem Börsengang ausgeübt und insgesamt neue Aktien ausgegeben haben 6,1468 Millionen Aktien.

Fand ihn auch klasse und sehr lesenswert

Super Artikel über WuXi im Kölner Stadtanzeiger😊👍🏼!!! Danke Summer.76 fürs Teilen🙏🏼

https://finance.sina.cn/hkstock/ggpj/2021-01-18/detail-ikftpnnx8713311.d.html?fromwap Zhongtai International daily morning news: ... We still recommend focusing on the current policy havens in the pharmaceutical industry-CXO, biotechnology, and Chinese medicine formula granules. We believe that the leading CXO industry WuXi Biologics (2269 HK) and WuXi AppTec (2359 HK) will still benefit from Increasing demand for innovative drug research and development. Considering the valuation factors, we have listed WuXi AppTec (2359 HK) as the top stock in the CXO sector for 2021, but we are still optimistic about WuXi Biologics (2269 HK). Both companies have increased by nearly 30% in the past month, and we recommend a fall Deploy at a later ***. ...